



UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

DIVISION OF
CORPORATION FINANCE

August 11, 2011

Via E-Mail

Kurt H. Jensen
Chief Financial Officer
Applied DNA Sciences, Inc.
25 Health Sciences Drive, Suite 215
Stony Brook, New York 11790

**Re: Applied DNA Sciences, Inc.
Form 10-K for the Fiscal Year ended September 30, 2010
Filed December 15, 2010
Amendment No. 1 to Form 10-K for the Fiscal Year ended
September 30, 2010
Filed July 25, 2011
File No. 2-90539**

Dear Mr. Jensen:

We have completed our review of your filing. We remind you that our comments or changes to disclosure in response to our comments do not foreclose the Commission from taking any action with respect to the company or the filing and the company may not assert staff comments as a defense in any proceeding initiated by the Commission or any person under the federal securities laws of the United States. We urge all persons who are responsible for the accuracy and adequacy of the disclosure in the filing to be certain that the filing includes the information the Securities Exchange Act of 1934 and all applicable rules require.

Sincerely,

/s/ Nudrat Salik
FOR
Jay Ingram
Legal Branch Chief

Cc: Via Email
Merrill M. Kraines, Esq.
Fulbright & Jaworski L.L.P.
666 Fifth Avenue
New York, New York 10103-3198